These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29664981)

  • 1. Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.
    de Andrade GC; de Oliveira Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):245-250. PubMed ID: 29664981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema.
    Ashraf M; Kayal HE; Souka AAR
    Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):399-405. PubMed ID: 28499051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant Bilateral Response in Diabetic Macular Edema After Single Unilateral Intravitreal Aflibercept Injection.
    Rahimy E; Nyong'o O; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2017 Feb; 48(2):167-169. PubMed ID: 28195620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
    Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive Release of Vitreomacular Traction With Aflibercept.
    Schwartz SG; Flynn HW
    Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):477-81. PubMed ID: 27183554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept.
    Calvo CM; Sridhar J; Shahlaee A; Ho AC
    Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):474-6. PubMed ID: 27183553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks.
    Hernández-Bel L; Cervera-Taulet E; Navarro-Palop C; Castro-Navarro V; Chiarri-Toumit C; Montero-Hernández J
    Ophthalmologica; 2019; 241(2):98-104. PubMed ID: 29996128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
    Wykoff CC; Le RT; Khurana RN; Brown DM; Ou WC; Wang R; Clark WL; Boyer DS;
    Am J Ophthalmol; 2017 Jan; 173():56-63. PubMed ID: 27702624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
    Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
    Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
    Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
    Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
    Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN.
    Terasaki H; Shiraki K; Ohji M; Metzig C; Schmelter T; Zeitz O; Sowade O; Kobayashi M; Vitti R; Berliner A; Shiraga F
    Retina; 2019 May; 39(5):938-947. PubMed ID: 29470308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema.
    Mansour AM; Dedhia C; Chhablani J
    Br J Ophthalmol; 2017 Feb; 101(2):166-169. PubMed ID: 27190127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.